Bax-based gene therapy techniques have demonstrated potential in eliciting bystander death effects in prostate cancer cells in conjunction with other apoptotic molecules such as Fas Ligand and TRAIL [71]. The gene discussed is BAX; the disease is prostate carcinoma.